Skip to content

Q Therapeutics, Inc.: 10-Q filed 2013-11-14

What Q Therapeutics, Inc. reported in its quarterly report filed 2013-11-14 (fiscal Q3 2013): 26 published measures, 89 facts as tagged in accession 0001193125-13-442024.

This filing

Form
10-Q (quarterly report)
Filed
2013-11-14
Fiscal period
fiscal Q3 2013
Accession
0001193125-13-442024 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Q Therapeutics, Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2013-09-30574,900USD
At 2012-12-311,305,932USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2013-09-30-2,464,299USD
At 2012-12-314,990USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2013-09-30330,365USD
At 2012-12-31794,207USD
At 2012-09-301,296,149USD
At 2011-12-312,741,519USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-1,756,260USD92
2013-01-01 to 2013-09-30-2,765,273USD273
2002-03-29 to 2013-09-30-23,257,551USD4204
2012-07-01 to 2012-09-30-601,446USD92
2012-01-01 to 2012-09-30-1,807,068USD274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2013-01-01 to 2013-09-30-690,040USD273
2002-03-29 to 2013-09-30-17,162,641USD4204
2012-01-01 to 2012-09-30-1,619,807USD274

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2013-01-01 to 2013-09-3023,802USD273
2002-03-29 to 2013-09-30431,273USD4204
2012-01-01 to 2012-09-302,363USD274

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2013-07-01 to 2013-09-3012,000USD92
2013-01-01 to 2013-09-3024,286USD273
2002-03-29 to 2013-09-301,397,445USD4204
2012-01-01 to 2012-09-307,229USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2013-01-01 to 2013-09-30250,000USD273
2002-03-29 to 2013-09-3017,924,279USD4204
2012-01-01 to 2012-09-30176,800USD274

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2013-09-3030,222USD
At 2012-12-3116,044USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2013-07-01 to 2013-09-3025,439USD92
2013-01-01 to 2013-09-3076,316USD273
2002-03-29 to 2013-09-30508,117USD4204
2012-07-01 to 2012-09-3040,445USD92
2012-01-01 to 2012-09-3095,912USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-1,691,093USD92
2013-01-01 to 2013-09-30-2,701,344USD273
2002-03-29 to 2013-09-30-21,420,312USD4204
2012-07-01 to 2012-09-30-601,102USD92
2012-01-01 to 2012-09-30-1,806,830USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2013-09-30537,165USD
At 2012-12-311,282,375USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2013-07-01 to 2013-09-3066,158USD92
2013-01-01 to 2013-09-3066,808USD273
2002-03-29 to 2013-09-302,178,222USD4204
2012-07-01 to 2012-09-302,136USD92
2012-01-01 to 2012-09-305,580USD274

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2013-09-303,039,199USD
At 2012-12-311,300,942USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2013-09-302,236,896USD
At 2012-12-311,203,365USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2013-07-01 to 2013-09-301,698,293USD92
2013-01-01 to 2013-09-302,720,830USD273
2002-03-29 to 2013-09-3022,812,957USD4204
2012-07-01 to 2012-09-30601,102USD92
2012-01-01 to 2012-09-301,814,059USD274

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2013-07-01 to 2013-09-307,200USD92
2013-01-01 to 2013-09-3019,486USD273
2002-03-29 to 2013-09-301,392,645USD4204
2012-01-01 to 2012-09-307,229USD274

Cost of revenue

Costs attributed to goods produced and sold and services provided during the period. This is not the sum of every operating expense.

PeriodValueUnitDays
2013-07-01 to 2013-09-304,800USD92
2013-01-01 to 2013-09-304,800USD273
2002-03-29 to 2013-09-304,800USD4204

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2013-07-01 to 2013-09-301,371,644USD92
2013-01-01 to 2013-09-301,642,591USD273
2002-03-29 to 2013-09-3012,615,483USD4204
2012-07-01 to 2012-09-30283,141USD92
2012-01-01 to 2012-09-30764,810USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2013-09-3024,936,833shares
At 2012-12-3124,761,832shares

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2013-09-3069,781USD
At 2012-12-319,685USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2013-09-302,800USD
At 2012-12-3110,366USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2013-07-01 to 2013-09-30326,649USD92
2013-01-01 to 2013-09-301,078,239USD273
2002-03-29 to 2013-09-3010,197,474USD4204
2012-07-01 to 2012-09-30317,961USD92
2012-01-01 to 2012-09-301,049,249USD274

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2013-07-01 to 2013-09-30991USD92
2013-01-01 to 2013-09-302,879USD273
2002-03-29 to 2013-09-30153,367USD4204
2012-07-01 to 2012-09-30769USD92
2012-01-01 to 2012-09-302,130USD274

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2013-07-01 to 2013-09-30-65,167USD92
2013-01-01 to 2013-09-30-63,929USD273
2002-03-29 to 2013-09-30-1,837,239USD4204
2012-07-01 to 2012-09-30-344USD92
2012-01-01 to 2012-09-30-238USD274

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2002-03-29 to 2013-09-303,821,137USD4204
2012-01-01 to 2012-09-30190,000USD274

Inspect the source

Entity
Q Therapeutics, Inc. / CIK 0001366541
Captured
SEC response SHA-256
44c4e52011cdb12665e730e871f0d1a160eb40f2d3802dae8e8edfdd09adf9be

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001366541.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))